How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo.

How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo.

How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo. &nbsp;

Healthcare: Earnings Round-up -- Celgene and Gilead Sciences

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: Earnings Round-up -- Celgene and Gilead Sciences

Sign up to save your podcasts

Healthcare: Earnings Round-up -- Celgene and Gilead Sciences

Healthcare: Earnings Round-up -- Celgene and Gilead Sciences